Study guide
4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation
Philippine Physician Licensure Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: PLE Structure, Eligibility & Study Strategy
1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan
2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle
2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction
3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems
3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments
4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems
4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation
5 Chapter 5: Physiology IV: Neurophysiology & Special Senses
5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses
6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death
6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death
7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning
7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws
8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics
8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics
9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics
9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock
10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection
10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology
11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology
11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura
12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology
12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors
13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry
13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism
14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry
14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure
15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back
15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes
16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin
16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands
17 Chapter 17: Anatomy III: Head, Neck & Histology
17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology
18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections
18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis
19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections
19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning
20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections
20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases
21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections
21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis
22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding
22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage
23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems
23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception
24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception
24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria
25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues
25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents
26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections
26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections
27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders
27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning
28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders
28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child
29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider
29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036
30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine
30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine
31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer
31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health
32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics
32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections
33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics
33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy
34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics
34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis
35 Chapter 35: Surgery I: Basic Surgical Principles
35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety
36 Chapter 36: Surgery II: Abdomen, Breast & Hernia
36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma
37 Chapter 37: Surgery III: Surgical Specialties
37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)
38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine
38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome
39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine
39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS
40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry
40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)
4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation
Key Takeaways Explain This Topic AI
GFR is about 125 mL/min (180 L/day); inulin clearance measures GFR, PAH clearance measures effective renal plasma flow, and the filtration fraction is about 20%.
Afferent arteriolar constriction (NSAIDs) lowers GFR and RPF together; efferent constriction (angiotensin II) raises filtration fraction, and ACE inhibitors reverse it.
The proximal tubule reabsorbs about two-thirds of filtered sodium and water, the thick ascending limb (NKCC2, loop diuretics) about 25%, the early distal tubule (NCC, thiazides) 5% to 8%, and the collecting duct fine-tunes sodium and water under aldosterone and ADH.
Kidneys excrete the daily fixed-acid load as titratable acid and ammonium, and each excreted H+ adds a new bicarbonate to the blood.
For metabolic acidosis, expected PaCO2 = 1.5 x HCO3- + 8 (plus or minus 2); the anion gap = Na+ - (Cl- + HCO3-), normally about 10 to 12.
Last updated: October 2026
Why this area matters
The TOS lists:
- body fluid compartments and the intake and losses that change them;
- the structure and function of the renal cortex and medulla;
- the determinants of renal blood flow and GFR;
- nephron transport;
- erythropoietin production and its targets;
blood pH regulation.
Every diuretic question in Pharmacology and every acid-base question in Medicine builds on this physiology.
Daily water balance
An adult takes in about 2.3 L of water a day : about 2.1 L from food and drink and about 0.2 L from metabolism. Losses at rest are roughly:
- 1.4 L in urine;
- 0.7 L of insensible loss through skin and lungs;
- 0.1 L in sweat;
0.1 L in feces.
Heat and heavy exercise can raise sweat loss to several liters a day, and fever raises insensible loss. Diarrhea, vomiting and burns produce large extracellular losses. The body fluid compartments themselves are described in the homeostasis section.
Kidney structure
The cortex contains glomeruli, proximal and distal convoluted tubules and cortical collecting ducts. The medulla contains the loops of Henle, vasa recta and medullary collecting ducts, arranged in renal pyramids.
About 85% of nephrons are cortical , with short loops.
About 15% are juxtamedullary , with long loops that reach deep into the medulla. These build the concentration gradient.
The juxtaglomerular apparatus sits where the distal tubule touches its own afferent arteriole. It has three parts: macula densa cells, renin-secreting granular cells and extraglomerular mesangial cells.
Glomerular Filtration, Clearance & Autoregulation
Glomerular filtration produces approximately 180 L/day 180\text{ L/day} 180 L/day ( 125 mL/min 125\text{ mL/min} 125 mL/min ) of ultrafiltrate across the three-layered glomerular filtration barrier (fenestrated capillary endothelium, negatively charged basement membrane rich in heparan sulfate, and podocyte foot processes with nephrin slit diaphragms).
Starling Forces Across the Glomerular Capillary
GFR = K f ⋅ [ ( P G C − P B S ) − ( π G C − π B S ) ] \text{GFR} = K_f \cdot \left[ (P_{GC} - P_{BS}) - (\pi_{GC} - \pi_{BS}) \right] GFR = K f ⋅ [ ( P GC − P BS ) − ( π GC − π BS ) ]
K f K_f K f : Ultrafiltration coefficient (product of surface area and hydraulic permeability).
P G C P_{GC} P GC (Glomerular Capillary Hydrostatic Pressure ≈ 50 – 60 mmHg \approx 50\text{--}60\text{ mmHg} ≈ 50 – 60 mmHg ): The primary driving force favoring filtration. Remains elevated and relatively flat along the capillary due to high downstream resistance from efferent arterioles.
P B S P_{BS} P BS (Bowman's Space Hydrostatic Pressure ≈ 10 – 15 mmHg \approx 10\text{--}15\text{ mmHg} ≈ 10 – 15 mmHg ): Opposes filtration. Increases in urinary tract obstruction (e.g., ureteral calculi, benign prostatic hyperplasia), which lowers GFR.
π G C \pi_{GC} π GC (Glomerular Capillary Oncotic Pressure ≈ 25 – 32 mmHg \approx 25\text{--}32\text{ mmHg} ≈ 25 – 32 mmHg ): Opposes filtration. Rises progressively from the afferent to efferent end as protein-free filtrate leaves the vascular space.
π B S \pi_{BS} π BS (Bowman's Space Oncotic Pressure): Effectively 0 mmHg 0\text{ mmHg} 0 mmHg in health because albumin cannot cross the filtration barrier.
Arteriolar Resistance & Filtration Fraction
Filtration Fraction (FF) = GFR RPF ≈ 125 mL/min 625 mL/min ≈ 20 % \text{Filtration Fraction (FF)} = \frac{\text{GFR}}{\text{RPF}} \approx \frac{125\text{ mL/min}}{625\text{ mL/min}} \approx 20\% Filtration Fraction (FF) = RPF GFR ≈ 625 mL/min 125 mL/min ≈ 20%
Afferent Arteriolar Constriction (e.g., NSAIDs inhibiting vasodilatory prostaglandins, high sympathetic tone): Reduces P G C P_{GC} P GC , thereby decreasing GFR and RPF in equal proportion; FF remains unchanged .
Efferent Arteriolar Constriction (e.g., low-to-moderate Angiotensin II): Restricts outflow from the glomerular tuft, increasing P G C P_{GC} P GC . GFR increases while RPF decreases; FF increases markedly .
ACE Inhibitors / ARBs : Inhibit angiotensin II, selectively dilating the efferent arteriole. This lowers P G C P_{GC} P GC and GFR while increasing RPF, reducing FF. This effect relieves intraglomerular hypertension, conferring long-term renoprotection in diabetic kidney disease despite an acute modest rise in serum creatinine.
Renal Clearance Calculations
Clearance ( C x C_x C x ) represents the volume of plasma completely cleared of a substance by the kidneys per unit time:
C x = U x ⋅ V P x C_x = \frac{U_x \cdot V}{P_x} C x = P x U x ⋅ V
Where U x U_x U x is urine concentration, V V V is urine flow rate (mL/min), and P x P_x P x is plasma concentration.
Inulin Clearance : Inulin is freely filtered and neither reabsorbed nor secreted along the nephron. Thus, C i n u l i n = GFR C_{inulin} = \text{GFR} C in u l in = GFR (the gold standard reference).
Creatinine Clearance : Endogenous metabolic byproduct of muscle creatine. Freely filtered but undergoes slight active secretion by proximal tubule organic cation transporters ( ∼ 10 % to 15 % \sim 10\%\text{ to }15\% ∼ 10% to 15% ). Consequently, C c r C_{cr} C cr slightly overestimates true GFR . Note that serum creatinine has an inverse exponential relationship with GFR: a rise in serum creatinine from 1.0 mg/dL 1.0\text{ mg/dL} 1.0 mg/dL to 2.0 mg/dL 2.0\text{ mg/dL} 2.0 mg/dL represents a loss of roughly 50 % 50\% 50% of functioning renal mass.
Para-aminohippuric Acid (PAH) Clearance : Freely filtered and actively secreted by organic anion transporters in the proximal tubule with nearly 100% extraction efficiency in a single pass. Thus, C P A H = Effective Renal Plasma Flow (ERPF) ≈ 600 mL/min C_{PAH} = \text{Effective Renal Plasma Flow (ERPF)} \approx 600\text{ mL/min} C P A H = Effective Renal Plasma Flow (ERPF) ≈ 600 mL/min .
Renal Blood Flow (RBF) : RBF = RPF 1 − Hematocrit ≈ 650 1 − 0.45 ≈ 1200 mL/min ( 20 % – 25 % of Cardiac Output ) \text{RBF} = \frac{\text{RPF}}{1 - \text{Hematocrit}} \approx \frac{650}{1 - 0.45} \approx 1200\text{ mL/min} \quad (20\%\text{--}25\%\text{ of Cardiac Output}) RBF = 1 − Hematocrit RPF ≈ 1 − 0.45 650 ≈ 1200 mL/min ( 20% – 25% of Cardiac Output )
Autoregulation of GFR
Renal autoregulation maintains nearly constant GFR and RBF across mean arterial pressures between 80 and 180 mmHg 80\text{ and }180\text{ mmHg} 80 and 180 mmHg through two mechanisms:
Myogenic Mechanism : Elevated arterial pressure stretches the vascular smooth muscle of the afferent arteriole, opening stretch-sensitive calcium channels to cause reflex vasoconstriction.
Tubuloglomerular Feedback (TGF) : Mediated by the juxtaglomerular apparatus. When elevated GFR increases luminal delivery of N a C l NaCl N a Cl to the macula densa (specialized epithelial cells in the thick ascending limb/early distal tubule), apical NKCC2 cotransporters absorb excess N a + Na^+ N a + and C l − Cl^- C l − . Intracellular ATP is degraded to adenosine , which binds A 1 A_1 A 1 receptors on adjacent extraglomerular mesangial and vascular smooth muscle cells, triggering afferent arteriolar vasoconstriction and suppressing renin release.
Segmental Tubular Solute & Water Transport
Nephron Segment Major Solute Transport Mechanisms Water Permeability Clinical & Pharmacological Correlations
Proximal Convoluted Tubule (PCT) 67% of filtered N a + Na^+ N a + , H 2 O H_2O H 2 O , C l − Cl^- C l − , K + K^+ K + reabsorbed isosmotically; 100% of glucose reabsorbed via SGLT2 ( S 1 S_1 S 1 ) and SGLT1 ( S 3 S_3 S 3 ); 100% of amino acids reabsorbed; 85% of H C O 3 − HCO_3^- H C O 3 − reabsorbed via apical NHE3 and carbonic anhydrase High (constitutive Aquaporin-1) SGLT2 inhibitors block glucose transport; Acetazolamide inhibits carbonic anhydrase; Fanconi syndrome: generalized proximal tubule failure
Thin Descending Limb of Henle Minimal solute transport; passive reabsorption of water driven by hypertonic medullary interstitium High (Aquaporin-1) Tubular fluid becomes maximally concentrated ( 1200 mOsm/kg 1200\text{ mOsm/kg} 1200 mOsm/kg at hairpin turn)
Thick Ascending Limb of Henle (TAL) Actively reabsorbs 25% of N a + Na^+ N a + , K + K^+ K + , 2 C l − 2 Cl^- 2 C l − via NKCC2 ; Apical ROMK potassium channels recycle K + K^+ K + into lumen, generating a + 8 to + 10 mV +8\text{ to }+10\text{ mV} + 8 to + 10 mV lumen-positive potential that drives paracellular C a 2 + Ca^{2+} C a 2 + and M g 2 + Mg^{2+} M g 2 + reabsorption Impermeable to water ("diluting segment") Loop diuretics (furosemide) inhibit NKCC2, dissipating the medullary gradient and causing calciuria; Bartter syndrome: genetic NKCC2/ROMK mutation mimicking loop diuretics
Early Distal Convoluted Tubule (DCT) Reabsorbs 5% to 8% of N a + Na^+ N a + and C l − Cl^- C l − via NCCT ; Transcellular C a 2 + Ca^{2+} C a 2 + reabsorption via apical TRPV5 channels and basolateral NCX, stimulated by PTH Impermeable to water (further dilutes urine) Thiazides inhibit NCCT, promoting natriuresis while enhancing C a 2 + Ca^{2+} C a 2 + reabsorption (hypercalcemia); Gitelman syndrome: genetic NCCT defect mimicking thiazides
Cortical & Medullary Collecting Duct Principal Cells : Reabsorb N a + Na^+ N a + via ENaC ; secrete K + K^+ K + via ROMK; stimulated by Aldosterone. α \alpha α -Intercalated Cells : Secrete H + H^+ H + via apical H + H^+ H + ATPase; reabsorb K + K^+ K + via H + / K + H^+/K^+ H + / K + ATPase; generate new H C O 3 − HCO_3^- H C O 3 − Variable: Regulated strictly by Vasopressin (ADH) via V 2 V_2 V 2 receptors and Aquaporin-2 (AQP2) insertion Potassium-sparing diuretics : amiloride blocks ENaC; spironolactone blocks aldosterone receptor; Liddle syndrome: gain-of-function ENaC mutation; Diabetes insipidus: lack of ADH (central) or V 2 V_2 V 2 /AQP2 defect (nephrogenic)
- Acid-Base Regulation & Anion Gap Analysis
- The Henderson-Hasselbalch Relationship
pH = 6.1 + log 10 ( [ H C O 3 − ] 0.03 ⋅ P a C O 2 ) \text{pH} = 6.1 + \log_{10}\left(\frac{[HCO_3^-]}{0.03 \cdot PaCO_2}\right) pH = 6.1 + lo g 10 ( 0.03 ⋅ P a C O 2 [ H C O 3 − ] )
Normal arterial reference values: pH 7.35 – 7.45 \text{pH } 7.35\text{--}7.45 pH 7.35 – 7.45 , [ H C O 3 − ] = 22 – 26 mEq/L [HCO_3^-] = 22\text{--}26\text{ mEq/L} [ H C O 3 − ] = 22 – 26 mEq/L , P a C O 2 = 35 – 45 mmHg PaCO_2 = 35\text{--}45\text{ mmHg} P a C O 2 = 35 – 45 mmHg .
Primary Disturbances & Compensatory Formulas
Metabolic Acidosis : Primary drop in [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] . Compensatory alveolar hyperventilation lowers P a C O 2 PaCO_2 P a C O 2 . Expected compensation is calculated using Winter's Formula : Expected P a C O 2 = ( 1.5 × [ H C O 3 − ] ) + 8 ± 2 \text{Expected } PaCO_2 = (1.5 \times [HCO_3^-]) + 8 \pm 2 Expected P a C O 2 = ( 1.5 × [ H C O 3 − ]) + 8 ± 2
If measured P a C O 2 > expected PaCO_2 > \text{expected} P a C O 2 > expected : Concurrent primary respiratory acidosis (hypoventilation, respiratory failure).
If measured P a C O 2 < expected PaCO_2 < \text{expected} P a C O 2 < expected : Concurrent primary respiratory alkalosis (hyperventilation, sepsis, salicylate toxicity).
Metabolic Alkalosis : Primary rise in [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] . Compensatory hypoventilation raises P a C O 2 PaCO_2 P a C O 2 : Δ P a C O 2 ≈ 0.7 × Δ [ H C O 3 − ] ( ceiling ∼ 55 – 60 mmHg ) \Delta PaCO_2 \approx 0.7 \times \Delta [HCO_3^-] \quad (\text{ceiling } \sim 55\text{--}60\text{ mmHg}) Δ P a C O 2 ≈ 0.7 × Δ [ H C O 3 − ] ( ceiling ∼ 55 – 60 mmHg )
Respiratory Acidosis : Primary elevation in P a C O 2 PaCO_2 P a C O 2 :
Acute : For each 10 mmHg 10\text{ mmHg} 10 mmHg rise in P a C O 2 PaCO_2 P a C O 2 , [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] increases by 1 mEq/L 1\text{ mEq/L} 1 mEq/L ( pH \text{pH} pH drops by 0.08 0.08 0.08 ).
Chronic : For each 10 mmHg 10\text{ mmHg} 10 mmHg rise in P a C O 2 PaCO_2 P a C O 2 , [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] increases by 3.5 – 4.0 mEq/L 3.5\text{--}4.0\text{ mEq/L} 3.5 – 4.0 mEq/L ( pH \text{pH} pH drops by 0.03 0.03 0.03 ).
Respiratory Alkalosis : Primary decrease in P a C O 2 PaCO_2 P a C O 2 :
Acute : For each 10 mmHg 10\text{ mmHg} 10 mmHg drop in P a C O 2 PaCO_2 P a C O 2 , [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] decreases by 2 mEq/L 2\text{ mEq/L} 2 mEq/L ( pH \text{pH} pH rises by 0.08 0.08 0.08 ).
Chronic : For each 10 mmHg 10\text{ mmHg} 10 mmHg drop in P a C O 2 PaCO_2 P a C O 2 , [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] decreases by 4 – 5 mEq/L 4\text{--}5\text{ mEq/L} 4 – 5 mEq/L ( pH \text{pH} pH rises by 0.03 0.03 0.03 ).
Serum Anion Gap Evaluation
Anion Gap (AG) = [ N a + ] − ( [ C l − ] + [ H C O 3 − ] ) ( Normal: 10 – 12 mEq/L ) \text{Anion Gap (AG)} = [Na^+] - ([Cl^-] + [HCO_3^-]) \quad (\text{Normal: } 10\text{--}12\text{ mEq/L}) Anion Gap (AG) = [ N a + ] − ([ C l − ] + [ H C O 3 − ]) ( Normal: 10 – 12 mEq/L )
Albumin Correction : Serum albumin carries negative charges accounting for the majority of normal unmeasured anions. For every 1 g/dL 1\text{ g/dL} 1 g/dL drop in serum albumin below 4.0 g/dL 4.0\text{ g/dL} 4.0 g/dL , the expected baseline AG drops by 2.5 mEq/L 2.5\text{ mEq/L} 2.5 mEq/L : Corrected AG = Observed AG + 2.5 × ( 4.0 − [ Albumin ] ) \text{Corrected AG} = \text{Observed AG} + 2.5 \times (4.0 - [\text{Albumin}]) Corrected AG = Observed AG + 2.5 × ( 4.0 − [ Albumin ])
High Anion Gap Metabolic Acidosis (MUDPILES / GOLDMARK) : Methanol, Uremia, Diabetic ketoacidosis, Propylene glycol, Isoniazid/Iron, Lactic acidosis, Ethylene glycol, Salicylates (aspirin: causes early respiratory alkalosis followed by high AG metabolic acidosis).
Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (HARDUP) : Hyperalimentation, Acetazolamide, Renal tubular acidosis (Types 1, 2, 4), Diarrhea (loss of H C O 3 − HCO_3^- H C O 3 − with proportional retention of C l − Cl^- C l − ), Ureteral diversion, Pancreatic fistulas.
Delta-Delta ( Δ / Δ \Delta/\Delta Δ/Δ ) Ratio : In high AG metabolic acidosis, compares the excess anion gap to the deficit in bicarbonate: Δ AG Δ [ H C O 3 − ] = AG − 12 24 − [ H C O 3 − ] \frac{\Delta \text{AG}}{\Delta [HCO_3^-]} = \frac{\text{AG} - 12}{24 - [HCO_3^-]} Δ [ H C O 3 − ] Δ AG = 24 − [ H C O 3 − ] AG − 12
Ratio < 0.8 < 0.8 < 0.8 : Mixed High AG and Normal AG metabolic acidosis.
Ratio 0.8 – 2.0 0.8\text{--}2.0 0.8 – 2.0 : Pure high anion gap metabolic acidosis.
Ratio > 2.0 > 2.0 > 2.0 : Concurrent metabolic alkalosis or pre-existing compensated chronic respiratory acidosis.
Concentrating and diluting the urine
The countercurrent multiplier works as follows. The thick ascending limb pumps NaCl into the interstitium without water. The descending limb loses water to the salty interstitium. Repeated along the loop, this builds a medullary gradient from about 300 to 1,200 mOsm/kg.
Urea recycling in the inner medullary collecting duct, which ADH stimulates through urea transporters, supplies about half of the inner-medullary osmolality.
The vasa recta act as countercurrent exchangers, so blood flow does not wash out the gradient.
With high ADH, aquaporin-2 lets collecting-duct water leave, producing urine of up to about 1,200 mOsm/kg. Without ADH, dilute urine as low as about 50 mOsm/kg is excreted.
Potassium handling
About 90% of filtered K+ is reabsorbed before the distal nephron. The amount excreted is set by principal-cell secretion , which increases with:
- aldosterone;
- high distal sodium delivery and flow (loop and thiazide diuretics cause hypokalemia);
- alkalosis;
a high plasma K+.
Potassium-sparing diuretics and ACE inhibitors reduce secretion and can cause hyperkalemia.
Erythropoietin
Peritubular interstitial (fibroblast-like) cells in the renal cortex sense oxygen through hypoxia-inducible factor. When oxygen delivery falls, they increase erythropoietin , which acts on erythroid progenitors (CFU-E) in the marrow to prevent apoptosis and expand red cell production. Chronic kidney disease causes a normocytic anemia that responds to erythropoiesis-stimulating agents once iron stores are adequate.
Renal acid excretion
Metabolism produces about 1 mEq/kg of fixed (non-volatile) acid a day , about 50 to 100 mEq in an adult. The kidney handles it in two steps:
It reclaims filtered bicarbonate , mostly in the proximal tubule through NHE3 and carbonic anhydrase.
It excretes H+ as titratable acid (mainly phosphate) and as ammonium . Ammonium comes from glutamine metabolism in proximal cells and can be increased many-fold in chronic acidosis.
Each H+ excreted generates a new HCO3- for the blood. Renal tubular acidosis results when bicarbonate reclamation (type 2, proximal) or H+ secretion (type 1, distal) fails, or when aldosterone action is deficient (type 4, hyperkalemic).